Click here to view online. Add this email to your safelist.

AstraZeneca logo

AstraZeneca agrees to buy US FDA Priority Review Voucher from Sobi

22 August 2019

AstraZeneca today announced that it has agreed to buy a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) for a total cash consideration of $95m from a subsidiary of Swedish Orphan Biovitrum AB (publ) (Sobi).

Read more  Read more

RSS Feed  RSS Feed Twitter  Follow us on Twitter LinkedIn  Follow us on LinkedIn
Legal notice and Terms of Use Privacy policy Cookie policy Site map © AstraZeneca 2019

For more information please visit astrazeneca.com.

If you would like to unsubscribe please click here.